TOMORROW 2018-05-31T21:44:30+00:00

Clinical Trials

May 31, 2018

TOMORROW: A multicenter, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension

  • Study Sponsor: Actelion
  • Institution: Actelion, a Janssen Pharmaceutical Company of Johnson and Johnson
  • Start Date: Tuesday, November 28, 2017
  • End Date: Thursday, July 14, 2022
  • Design: Background treatment allowed
  • Age range (years): From 2 to 17
  • Type of PH
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • Toxic – APAH
    • HIV – APAH
  • Study Duration for individual patient: Up to 6 years
  • Contact: https://clinicaltrials.gov/ct2/show/NCT02932410?term=TOMORROW&rank=1
  • Listing on clinicaltrials.gov